Trial Profile
Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Therapeutic Use
- Acronyms DECADE
- 24 Sep 2019 Results assessing to evaluate serologic response in patients following vaccination with the tetravalent meningococcal conjugate vaccine published in the Vaccine
- 20 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology